What is Boston Scientific Corporation's earnings per share (EPS)?

Boston Scientific Corporation (BSX) reported diluted earnings per share of $1.94 for fiscal year 2025. This represents a 55.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Boston Scientific Corporation (BSX) Financials

BSX

Trailing 12 months to June 30, 2026

Revenue $21.0B +13.5% YoY

Net Income $3.7B +46.9% YoY

EPS (Diluted) $2.47 +47.0% YoY

Free Cash Flow $3.6B +4.0% YoY

Market Cap $61.7B as of Oct 3, 2026

Price / Sales 2.9x on $21.0B revenue, trailing 12 months to June 30, 2026

Price / Earnings 16.8x on $3.7B net income, trailing 12 months to June 30, 2026

Price / Book 2.5x on $24.9B equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 3, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 3, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BSX SEC filings page.

Boston Scientific Corporation (BSX) reported $21.0B in revenue over the twelve months to Jun 30, 2026, up 13.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BSX FY2025 2026-10-03

Boston Scientific is turning faster sales growth into even faster profit and cash generation, while goodwill weighs heavily on the asset base.

Operating cash flow rose from $2.5B to $4.5B across the reported period, showing that expansion translated into cash rather than remaining confined to accounting earnings. Operating margin widened from 16.5% to 18.0% over the same span, so the stronger cash result accompanied improved business economics.

Gross margin stayed close to 69.0% through FY2025, while operating margin reached 18.0%; because production economics were broadly stable, the additional profit appears to have come below gross profit through operating-cost absorption or mix, not a major change in unit production margin.

Goodwill concentration reached $18.3B, roughly 42.0% of assets, so reported assets contain a substantial intangible component rather than being entirely tangible backing. Short-term flexibility improved as the current ratio recovered to 1.6x from 1.1x, even as the asset base became more goodwill-heavy.

Financial Health Signals

Financial Health Score 65/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Boston Scientific Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Boston Scientific Corporation has an operating margin of 18.0%, meaning the company retains $18 of operating profit per $100 of revenue. This strong profitability earns a score of 81/100, reflecting efficient cost management and pricing power. This is up from 15.5% the prior year.

Growth

Boston Scientific Corporation's revenue surged 19.9% year-over-year to $20.1B, reflecting rapid business expansion. This strong growth earns a score of 81/100.

Leverage

Boston Scientific Corporation has a moderate D/E ratio of 0.46. This balance of debt and equity financing earns a leverage score of 34/100.

Liquidity

Boston Scientific Corporation's current ratio of 1.62 indicates adequate short-term liquidity, earning a score of 46/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Boston Scientific Corporation converts 18.2% of revenue into free cash flow ($3.7B). This strong cash generation earns a score of 81/100.

Returns

Boston Scientific Corporation earns a strong 11.9% return on equity (ROE), meaning it generates $12 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 65/100. This is up from 8.5% the prior year.

Altman Z-Score Grey Zone

2.91

Boston Scientific Corporation scores 2.91, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($61.7B) relative to total liabilities ($19.4B). This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong

7/9

Boston Scientific Corporation passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.57x

For every $1 of reported earnings, Boston Scientific Corporation generates $1.57 in operating cash flow ($4.5B OCF vs $2.9B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

10.35x

Boston Scientific Corporation earns $10.35 in operating income for every $1 of interest expense ($3.6B vs $349.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$5.4B

YoY+7.5%

QoQ+4.6%

5Y CAGR+12.1%

10Y CAGR+9.8%

Boston Scientific Corporation generated $5.4B in revenue in Q2 2026. This represents an increase of 7.5% from the same quarter a year earlier. Against the prior quarter it is up 4.6%.

EBITDA

$1.5B

YoY+32.7%

QoQ+5.6%

5Y CAGR+23.9%

Boston Scientific Corporation's EBITDA was $1.5B in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 32.7% from the same quarter a year earlier. Against the prior quarter it is up 5.6%.

Net Income

$905.0M

YoY+13.8%

QoQ-32.4%

5Y CAGR+37.2%

Boston Scientific Corporation reported $905.0M in net income in Q2 2026. This represents an increase of 13.8% from the same quarter a year earlier. Against the prior quarter it is down 32.4%.

EPS (Diluted)

$0.61

YoY+15.1%

QoQ-32.2%

5Y CAGR+38.4%

Boston Scientific Corporation earned $0.61 per diluted share (EPS) in Q2 2026. This represents an increase of 15.1% from the same quarter a year earlier. Against the prior quarter it is down 32.2%.

Cash & Balance Sheet

Free Cash Flow

$1.3B

YoY+13.3%

QoQ+648.0%

5Y CAGR+19.0%

10Y CAGR+14.1%

Boston Scientific Corporation generated $1.3B in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 13.3% from the same quarter a year earlier. Against the prior quarter it is up 648.0%.

Cash & Debt

$539.0M

YoY+0.9%

QoQ-62.9%

5Y CAGR-27.4%

10Y CAGR+2.1%

Boston Scientific Corporation held $539.0M in cash against $10.9B in long-term debt as of Q2 2026.

Shares Outstanding

1.45B

YoY-2.2%

QoQ-2.5%

5Y CAGR+0.4%

10Y CAGR+0.6%

Boston Scientific Corporation had 1.45B shares outstanding in Q2 2026. This represents a decrease of 2.2% from the same quarter a year earlier. Against the prior quarter it is down 2.5%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

70.7%

YoY+3.1pp

QoQ+1.2pp

5Y change+1.4pp

10Y change+0.8pp

Boston Scientific Corporation's gross margin was 70.7% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 3.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.2 percentage points.

Operating Margin

21.6%

YoY+5.5pp

QoQ+0.5pp

5Y change+13.1pp

10Y change+37.4pp

Boston Scientific Corporation's operating margin was 21.6% in Q2 2026, reflecting core business profitability. This is up 5.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.5 percentage points.

Net Margin

16.6%

YoY+0.9pp

QoQ-9.1pp

5Y change+10.6pp

10Y change+26.4pp

Boston Scientific Corporation's net profit margin was 16.6% in Q2 2026, showing the share of revenue converted to profit. This is up 0.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 9.1 percentage points.

Return on Equity

3.6%

YoY+0.1pp

QoQ-1.6pp

5Y change+2.5pp

10Y change+7.0pp

Boston Scientific Corporation's ROE was 3.6% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.6 percentage points.

Capital Allocation

R&D Spending

$554.0M

YoY+5.3%

QoQ+7.4%

5Y CAGR+13.2%

10Y CAGR+9.6%

Boston Scientific Corporation invested $554.0M in research and development in Q2 2026. This represents an increase of 5.3% from the same quarter a year earlier. Against the prior quarter it is up 7.4%.

Capital Expenditures

$195.0M

YoY+24.2%

QoQ+10.2%

5Y CAGR+13.0%

10Y CAGR+9.6%

Boston Scientific Corporation invested $195.0M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 24.2% from the same quarter a year earlier. Against the prior quarter it is up 10.2%.

Share Buybacks

Not reported for Q2 2026.

BSX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BSX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$21.0B	$20.1B+19.9%	$16.7B+17.6%	$14.2B+12.3%	$12.7B+6.7%	$11.9B+19.9%	$9.9B-7.7%	$10.7B+9.3%	$9.8B+8.6%	$9.0B-0.3%	$9.1B+12.5%	$8.1B+8.1%	$7.5B+5.5%	$7.1B+1.6%	$7.0B-8.7%	$7.6B
Cost of Revenue	$6.3B	$6.2B+18.3%	$5.3B+21.0%	$4.3B+9.8%	$4.0B+6.6%	$3.7B+7.1%	$3.5B+11.2%	$3.1B+10.8%	$2.8B+8.5%	$2.6B+7.0%	$2.4B+11.6%	$2.2B-1.7%	$2.2B+1.7%	$2.2B-7.4%	$2.3B-11.7%	$2.7B
Gross Profit	$14.7B	$13.9B+20.6%	$11.5B+16.1%	$9.9B+13.4%	$8.7B+6.7%	$8.2B+26.8%	$6.4B-15.4%	$7.6B+8.7%	$7.0B+8.6%	$6.5B+8.3%	$6.0B+12.4%	$5.3B+2.6%	$5.2B+4.0%	$5.0B+1.4%	$4.9B-1.3%	$5.0B
R&D Expenses	$2.2B	$2.1B+27.1%	$1.6B+14.2%	$1.4B+6.9%	$1.3B+9.9%	$1.2B+5.3%	$1.1B-2.6%	$1.2B+5.5%	$1.1B+11.6%	$997.0M+8.4%	$920.0M+5.0%	$876.0M+7.2%	$817.0M-5.1%	$861.0M-2.8%	$886.0M-1.0%	$895.0M
SG&A Expenses	$7.2B	$6.9B+15.1%	$6.0B+15.3%	$5.2B+14.8%	$4.5B+3.7%	$4.4B+15.1%	$3.8B-3.9%	$3.9B+10.4%	$3.6B+8.3%	$3.3B+6.3%	$3.1B+7.9%	$2.9B-1.0%	$2.9B+8.5%	$2.7B+5.5%	$2.5B+1.9%	$2.5B
Operating Income	$4.2B	$3.6B+38.8%	$2.6B+11.1%	$2.3B+42.1%	$1.6B+37.5%	$1.2B+1598.8%	-$80.0M-105.3%	$1.5B+0.8%	$1.5B+17.2%	$1.3B+187.5%	$447.0M+258.0%	-$283.0M+6.0%	-$301.0M-350.8%	$120.0M+103.1%	-$3.9B-527.9%	$904.0M
EBITDA	N/A	$5.0B+28.6%	$3.9B+9.4%	$3.5B+27.1%	$2.8B+21.5%	$2.3B+119.8%	$1.0B-58.8%	$2.5B+5.4%	$2.4B+12.7%	$2.1B+68.7%	$1.3B+159.7%	$486.0M+14.6%	$424.0M-47.6%	$809.0M+125.4%	-$3.2B-296.5%	$1.6B
Interest Expense	$363.0M	$349.0M+14.4%	$305.0M+15.1%	$265.0M-43.6%	$470.0M+37.8%	$341.0M-5.5%	$361.0M-23.7%	$473.0M+96.3%	$241.0M+5.2%	$229.0M-1.7%	$233.0M-18.0%	$284.0M+31.5%	$216.0M-33.3%	$324.0M+24.1%	$261.0M-7.1%	$281.0M
Income Tax	$193.0M	$493.0M+13.1%	$436.0M+10.9%	$393.0M-11.3%	$443.0M+1130.6%	$36.0M+1700.0%	$2.0M+100.0%	-$4.0B-1511.6%	-$249.0M-130.1%	$828.0M+587.1%	-$170.0M+58.6%	-$411.0M-5.4%	-$390.0M-282.4%	-$102.0M-161.5%	-$39.0M-119.4%	$201.0M
Net Income	$3.7B	$2.9B+56.7%	$1.8B+16.0%	$1.6B+128.1%	$698.0M-32.9%	$1.0B+1369.5%	-$82.0M-101.7%	$4.7B+181.3%	$1.7B+1506.7%	$104.0M-70.0%	$347.0M+245.2%	-$239.0M-100.8%	-$119.0M+1.7%	-$121.0M+97.0%	-$4.1B-1022.4%	$441.0M
EPS (Basic)	N/A	$1.96+55.6%	$1.26+16.7%	$1.08+140.0%	$0.45-34.8%	$0.69+962.5%	-$0.08-102.4%	$3.38+179.3%	$1.21+1412.5%	$0.08-69.2%	$0.26+244.4%	-$0.18-100.0%	-$0.090.0%	-$0.09+96.9%	-$2.89-1096.6%	$0.29
EPS (Diluted)	$2.47	$1.94+55.2%	$1.25+16.8%	$1.07+137.8%	$0.45-34.8%	$0.69+962.5%	-$0.08-102.4%	$3.33+179.8%	$1.19+1387.5%	$0.08-68.0%	$0.25+238.9%	-$0.18-100.0%	-$0.090.0%	-$0.09+96.9%	-$2.89-1096.6%	$0.29
Diluted Shares (Avg)	N/A	1.49B+0.6%	1.49B+1.5%	1.46B+1.7%	1.44B+0.4%	1.43B+1.2%	1.42B+0.4%	1.41B+0.7%	1.40B+0.6%	1.39B+1.1%	1.38B+2.7%	1.34B+1.3%	1.32B-1.3%	1.34B-4.7%	1.41B-7.4%	1.52B

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$5.4B+7.5%	$5.2B+11.6%	$5.3B+15.8%	$5.1B+20.3%	$5.1B+22.8%	$4.7B+20.9%	$4.6B+22.5%	$4.2B+19.3%
Cost of Revenue	$1.6B-2.6%	$1.6B+9.4%	$1.6B+9.7%	$1.5B+16.1%	$1.6B+28.9%	$1.5B+20.2%	$1.5B+27.9%	$1.3B+19.2%
Gross Profit	$3.8B+12.4%	$3.6B+12.6%	$3.7B+18.8%	$3.5B+22.3%	$3.4B+20.1%	$3.2B+21.2%	$3.1B+20.0%	$2.9B+19.4%
R&D Expenses	$554.0M+5.3%	$516.0M+16.5%	$569.0M+24.0%	$514.0M+26.3%	$526.0M+37.3%	$443.0M+21.0%	$459.0M+26.8%	$407.0M+14.3%
SG&A Expenses	$1.8B+5.1%	$1.8B+11.5%	$1.8B+13.7%	$1.7B+11.5%	$1.7B+18.7%	$1.6B+17.1%	$1.6B+16.9%	$1.6B+25.8%
Operating Income	$1.2B+43.8%	$1.1B+19.5%	$825.0M+22.2%	$1.0B+43.0%	$819.0M+57.5%	$921.0M+36.4%	$675.0M+15.6%	$733.0M+5.8%
EBITDA	$1.5B+32.7%	$1.5B+16.5%	$1.2B+16.4%	$1.4B+33.7%	$1.2B+39.0%	$1.2B+27.3%	$1.0B+14.1%	$1.0B+4.6%
Interest Expense	$96.0M+6.7%	$90.0M+9.8%	$90.0M+12.5%	$87.0M+10.1%	$90.0M+16.9%	$82.0M+18.8%	$80.0M+25.0%	$79.0M+19.7%
Income Tax	$155.0M+6.2%	-$176.0M-232.3%	$31.0M+34.8%	$183.0M-8.5%	$146.0M+49.0%	$133.0M+15.7%	$23.0M+2200.0%	$200.0M+90.5%
Net Income	$905.0M+13.8%	$1.3B+99.3%	$670.0M+19.0%	$755.0M+61.3%	$795.0M+146.9%	$672.0M+36.3%	$563.0M+11.7%	$468.0M-7.1%
EPS (Basic)	$0.62+14.8%	$0.90+95.7%	$0.46+21.1%	$0.51+59.4%	$0.54+145.5%	$0.46+35.3%	$0.38+11.8%	$0.32-5.9%
EPS (Diluted)	$0.61+15.1%	$0.90+100.0%	$0.45+18.4%	$0.51+59.4%	$0.53+140.9%	$0.45+36.4%	$0.38+11.8%	$0.32-5.9%
Diluted Shares (Avg)	1.47B-1.3%	1.50B+0.1%	N/A	1.50B+0.5%	1.49B+0.6%	1.49B+0.8%	N/A	1.49B+0.8%

BSX Balance Sheet

BSX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$43.7B+10.9%	$39.4B+12.1%	$35.1B+8.2%	$32.5B+0.7%	$32.2B+4.7%	$30.8B+0.7%	$30.6B+45.6%	$21.0B+10.3%	$19.0B+5.2%	$18.1B-0.2%	$18.1B+6.5%	$17.0B+2.7%	$16.6B-3.4%	$17.2B-19.4%	$21.3B
Current Assets	$8.8B+27.1%	$6.9B+6.2%	$6.5B+13.1%	$5.8B-8.8%	$6.3B-5.6%	$6.7B+42.5%	$4.7B+17.4%	$4.0B+4.7%	$3.8B+18.0%	$3.2B-6.7%	$3.5B-3.7%	$3.6B+19.8%	$3.0B-0.4%	$3.0B-2.7%	$3.1B
Cash & Equivalents	$2.0B+374.6%	$414.0M-52.1%	$865.0M-6.8%	$928.0M-51.8%	$1.9B+11.0%	$1.7B+699.1%	$217.0M+48.6%	$146.0M-22.3%	$188.0M-4.1%	$196.0M-38.6%	$319.0M-45.7%	$587.0M+170.5%	$217.0M+4.8%	$207.0M-22.5%	$267.0M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$2.9B+4.7%	$2.8B+13.1%	$2.5B+33.0%	$1.9B+16.0%	$1.6B+19.2%	$1.4B-14.4%	$1.6B+35.4%	$1.2B+8.2%	$1.1B+12.9%	$955.0M-6.0%	$1.0B+7.4%	$946.0M+5.5%	$897.0M+1.5%	$884.0M-5.0%	$931.0M
Long-Term Investments	$681.0M	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$18.3B+7.0%	$17.1B+18.8%	$14.4B+11.4%	$12.9B+7.8%	$12.0B+20.5%	$10.0B-2.2%	$10.2B+28.6%	$7.9B+13.0%	$7.0B+4.8%	$6.7B+3.2%	$6.5B+9.7%	$5.9B+3.6%	$5.7B-4.7%	$6.0B-38.8%	$9.8B
Total Liabilities	$19.4B+10.3%	$17.6B+11.2%	$15.9B+6.4%	$14.9B-4.6%	$15.6B+1.0%	$15.5B-7.4%	$16.7B+36.0%	$12.3B+2.0%	$12.0B+5.9%	$11.4B-3.8%	$11.8B+11.8%	$10.6B+5.3%	$10.0B-2.5%	$10.3B+3.5%	$9.9B
Current Liabilities	$5.4B-15.0%	$6.4B+29.7%	$4.9B+29.7%	$3.8B-11.0%	$4.3B+16.1%	$3.7B-24.4%	$4.9B-7.5%	$5.3B-7.0%	$5.7B+57.6%	$3.6B+47.6%	$2.4B-14.6%	$2.8B+56.0%	$1.8B+2.9%	$1.8B-1.9%	$1.8B
Non-Current Liabilities	$14.0B+24.7%	$11.2B+2.8%	$10.9B-1.6%	$11.1B-2.1%	$11.3B-3.7%	$11.8B-0.4%	$11.8B+68.6%	$7.0B+10.0%	$6.4B-18.0%	$7.8B-17.1%	$9.4B+21.5%	$7.7B-5.9%	$8.2B-3.6%	$8.5B+4.7%	$8.1B
Long-Term Debt	$11.1B+24.2%	$9.0B+4.6%	$8.6B-3.9%	$8.9B+1.3%	$8.8B-3.6%	$9.1B+6.3%	$8.6B+78.9%	$4.8B+25.9%	$3.8B-29.6%	$5.4B-4.5%	$5.7B+47.7%	$3.8B-9.3%	$4.2B-0.4%	$4.3B-0.1%	$4.3B
Total Equity	$24.2B+11.3%	$21.8B+12.9%	$19.3B+9.7%	$17.6B+5.7%	$16.6B+8.5%	$15.3B+10.4%	$13.9B+59.0%	$8.7B+24.4%	$7.0B+4.1%	$6.7B+6.5%	$6.3B-2.1%	$6.5B-1.3%	$6.5B-4.8%	$6.9B-39.5%	$11.4B
Retained Earnings	$5.6B+108.4%	$2.7B+226.4%	$819.0M+209.2%	-$750.0M+46.1%	-$1.4B+41.5%	-$2.4B-5.5%	-$2.3B+67.6%	-$7.0B+17.1%	-$8.4B+2.2%	-$8.6B+3.9%	-$8.9B-2.7%	-$8.7B-1.4%	-$8.6B-1.4%	-$8.4B-92.9%	-$4.4B

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$45.2B+8.8%	$44.4B+10.5%	$43.7B+10.9%	$42.7B+12.2%	$41.6B+12.0%	$40.1B+9.5%	$39.4B+12.1%	$38.1B+11.9%
Current Assets	$8.0B+12.0%	$8.7B+18.4%	$8.8B+27.1%	$8.0B-8.3%	$7.1B-20.8%	$7.3B-10.4%	$6.9B+6.2%	$8.8B+34.7%
Cash & Equivalents	$539.0M+0.9%	$1.5B+100.4%	$2.0B+374.6%	$1.3B-49.0%	$534.0M-81.7%	$725.0M-68.9%	$414.0M-52.1%	$2.5B+162.8%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$3.2B+13.1%	$3.1B+8.7%	$2.9B+4.7%	$2.9B+6.1%	$2.9B+9.7%	$2.9B+11.9%	$2.8B+13.1%	$2.8B+14.5%
Long-Term Investments	$2.2B	$0	$681.0M	$0	$0	$0	$0	$0
Goodwill	$18.6B+3.1%	$18.5B+6.9%	$18.3B+7.0%	$18.2B+21.2%	$18.1B+25.6%	$17.3B+20.7%	$17.1B+18.8%	$15.0B+10.5%
Total Liabilities	$20.3B+6.0%	$18.5B+3.1%	$19.4B+10.3%	$19.3B+11.2%	$19.1B+14.4%	$17.9B+7.1%	$17.6B+11.2%	$17.4B+14.6%
Current Liabilities	$6.4B+23.9%	$4.6B-9.6%	$5.4B-15.0%	$5.3B-9.8%	$5.2B-6.9%	$5.1B+2.9%	$6.4B+29.7%	$5.9B+29.1%
Non-Current Liabilities	$13.9B-0.7%	$13.9B+8.1%	$14.0B+24.7%	$14.0B+22.0%	$14.0B+25.0%	$12.9B+8.8%	$11.2B+2.8%	$11.5B+8.3%
Long-Term Debt	$10.9B-1.7%	$11.0B+4.3%	$11.1B+24.2%	$11.1B+20.4%	$11.1B+23.5%	$10.5B+10.5%	$9.0B+4.6%	$9.2B+10.1%
Total Equity	$24.9B+11.2%	$25.9B+16.4%	$24.2B+11.3%	$23.4B+13.0%	$22.4B+10.0%	$22.2B+11.5%	$21.8B+12.9%	$20.7B+9.6%
Retained Earnings	$7.8B+88.7%	$6.9B+106.5%	$5.6B+108.4%	$4.9B+132.5%	$4.1B+152.8%	$3.3B+154.7%	$2.7B+226.4%	$2.1B+568.9%

Not reported in any period shown, so not listed: Accounts Receivable.

BSX Cash Flow Statement

BSX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$4.5B	$4.5B+32.0%	$3.4B+37.2%	$2.5B+64.0%	$1.5B-18.4%	$1.9B+24.0%	$1.5B-17.9%	$1.8B+492.3%	$310.0M-78.3%	$1.4B+20.6%	$1.2B+71.1%	$691.0M-45.5%	$1.3B+14.3%	$1.1B-13.3%	$1.3B+27.0%	$1.0B
Depreciation & Amortization	N/A	$1.4B+7.8%	$1.3B+6.1%	$1.2B+5.3%	$1.1B+3.9%	$1.1B-2.7%	$1.1B+11.1%	$1.0B+13.1%	$894.0M+5.9%	$844.0M+3.6%	$815.0M+6.0%	$769.0M+6.1%	$725.0M+5.2%	$689.0M+0.9%	$683.0M-4.7%	$717.0M
Stock-Based Compensation	N/A	$299.0M+12.4%	$266.0M+14.2%	$233.0M+5.9%	$220.0M+13.4%	$194.0M+14.1%	$170.0M+8.3%	$157.0M+12.1%	$140.0M+10.2%	$127.0M+9.5%	$116.0M+8.4%	$107.0M+3.9%	$103.0M-1.9%	$105.0M-2.8%	$108.0M-15.6%	$128.0M
Capital Expenditures	$904.0M	$876.0M+10.9%	$790.0M+11.1%	$711.0M+20.9%	$588.0M+6.1%	$554.0M+47.3%	$376.0M-18.4%	$461.0M+45.9%	$316.0M-0.9%	$319.0M-15.2%	$376.0M+52.2%	$247.0M-4.6%	$259.0M+5.7%	$245.0M+8.4%	$226.0M-25.7%	$304.0M
Free Cash Flow	$3.6B	$3.7B+38.3%	$2.6B+47.6%	$1.8B+91.0%	$938.0M-28.7%	$1.3B+16.3%	$1.1B-17.7%	$1.4B+23016.7%	-$6.0M-100.5%	$1.1B+37.3%	$806.0M+81.5%	$444.0M-56.0%	$1.0B+16.8%	$865.0M-17.9%	$1.1B+49.7%	$704.0M
Investing Cash Flow	-$3.6B	-$2.6B+53.6%	-$5.7B-120.9%	-$2.6B-28.0%	-$2.0B-25.9%	-$1.6B-288.6%	-$411.0M+91.8%	-$5.0B-162.4%	-$1.9B-90.2%	-$1.0B-13.9%	-$887.0M+59.4%	-$2.2B-193.4%	-$745.0M-56.8%	-$475.0M+18.0%	-$579.0M-174.6%	$776.0M
Financing Cash Flow	-$958.0M	-$395.0M-121.8%	$1.8B+36180.0%	$5.0M+100.9%	-$548.0M-476.8%	-$95.0M-132.4%	$293.0M-90.1%	$3.0B+107.6%	$1.4B+1201.8%	$110.0M+153.4%	-$206.0M-116.1%	$1.3B+950.7%	-$150.0M+76.0%	-$624.0M+18.3%	-$764.0M+55.8%	-$1.7B
Dividends Paid	N/A	N/A	$0-100.0%	$28.0M-49.1%	$55.0M0.0%	$55.0M+96.4%	$28.0M	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	$0	$0-100.0%	$535.0M	$0	$0	N/A	$0	$0-100.0%	$125.0M-75.0%	$500.0M-16.7%	$600.0M+22.0%	$492.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$1.5B+14.6%	$348.0M-35.7%	$1.4B-6.3%	$1.3B+34.0%	$1.3B+58.2%	$541.0M+229.9%	$1.5B+52.1%	$1.0B+43.6%
Depreciation & Amortization	$355.0M+5.7%	$351.0M+8.0%	$365.0M+4.9%	$342.0M+11.4%	$336.0M+8.0%	$325.0M+6.9%	$348.0M+11.2%	$307.0M+2.0%
Stock-Based Compensation	N/A	$83.0M+12.2%	N/A	N/A	N/A	$74.0M+17.5%	N/A	N/A
Capital Expenditures	$195.0M+24.2%	$177.0M-5.3%	$351.0M+26.7%	$181.0M+1.1%	$157.0M+1.3%	$187.0M+4.5%	$277.0M+3.7%	$179.0M-5.8%
Free Cash Flow	$1.3B+13.3%	$171.0M-51.7%	$1.0B-14.1%	$1.2B+41.2%	$1.1B+71.6%	$354.0M+2460.0%	$1.2B+70.9%	$823.0M+62.0%
Investing Cash Flow	-$2.0B-73.7%	-$591.0M-18.2%	-$512.0M+86.2%	-$502.0M+64.8%	-$1.1B-315.5%	-$500.0M-75.4%	-$3.7B-251.8%	-$1.4B-624.4%
Financing Cash Flow	-$410.0M-20.6%	-$260.0M-211.6%	-$184.0M-186.0%	-$104.0M-1585.7%	-$340.0M-1516.7%	$233.0M-85.1%	$214.0M+1326.7%	$7.0M-56.3%
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0

Not reported in any period shown, so not listed: Share Buybacks.

BSX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BSX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	69.0%+0.4pp	68.6%-0.9pp	69.5%+0.7pp	68.8%0.0pp	68.8%+3.7pp	65.0%-5.9pp	71.0%-0.4pp	71.4%0.0pp	71.3%+5.6pp	65.7%0.0pp	65.7%-3.5pp	69.3%-1.0pp	70.3%-0.2pp	70.4%+5.3pp	65.1%
Operating Margin	18.0%+2.5pp	15.5%-0.9pp	16.4%+3.5pp	13.0%+2.9pp	10.1%+10.9pp	-0.8%-14.9pp	14.1%-1.2pp	15.3%+1.1pp	14.2%+9.3pp	4.9%+8.4pp	-3.5%+0.5pp	-4.0%-5.7pp	1.7%+57.3pp	-55.6%-67.5pp	11.9%
Net Margin	14.4%+3.4pp	11.0%-0.2pp	11.2%+5.7pp	5.5%-3.3pp	8.8%+9.6pp	-0.8%-44.6pp	43.8%+26.8pp	17.0%+15.9pp	1.1%-2.7pp	3.8%+6.8pp	-3.0%-1.4pp	-1.6%+0.1pp	-1.7%+56.8pp	-58.5%-64.3pp	5.8%
Return on Equity	11.9%+3.5pp	8.5%+0.2pp	8.3%+4.3pp	4.0%-2.3pp	6.3%+6.8pp	-0.5%-34.4pp	33.9%+14.7pp	19.1%+17.7pp	1.5%-3.7pp	5.1%+8.9pp	-3.8%-1.9pp	-1.8%0.0pp	-1.8%+57.4pp	-59.2%-63.1pp	3.9%
Return on Assets	6.6%+1.9pp	4.7%+0.2pp	4.5%+2.4pp	2.1%-1.1pp	3.2%+3.5pp	-0.3%-15.7pp	15.4%+7.4pp	8.0%+7.4pp	0.5%-1.4pp	1.9%+3.2pp	-1.3%-0.6pp	-0.7%0.0pp	-0.7%+23.0pp	-23.7%-25.8pp	2.1%
Current Ratio	1.62+0.5x	1.08-0.2x	1.32-0.2x	1.510.0x	1.48-0.3x	1.82+0.9x	0.97+0.2x	0.76+0.1x	0.68-0.2x	0.90-0.5x	1.43+0.2x	1.27-0.4x	1.65-0.1x	1.710.0x	1.72
Debt-to-Equity	0.460.0x	0.410.0x	0.44-0.1x	0.510.0x	0.53-0.1x	0.600.0x	0.62+0.1x	0.550.0x	0.54-0.3x	0.81-0.1x	0.90+0.3x	0.59-0.1x	0.650.0x	0.62+0.2x	0.38
Asset Turnover	0.460.0x	0.430.0x	0.410.0x	0.390.0x	0.370.0x	0.320.0x	0.35-0.1x	0.470.0x	0.480.0x	0.50+0.1x	0.440.0x	0.440.0x	0.430.0x	0.410.0x	0.36
FCF Margin	18.2%+2.4pp	15.8%+3.2pp	12.6%+5.2pp	7.4%-3.7pp	11.1%-0.3pp	11.4%-1.4pp	12.8%+12.9pp	-0.1%-12.3pp	12.2%+3.4pp	8.9%+3.4pp	5.5%-8.0pp	13.5%+1.3pp	12.2%-2.9pp	15.2%+5.9pp	9.2%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	70.7%+3.1pp	69.5%+0.6pp	69.6%+1.7pp	69.9%+1.1pp	67.7%-1.5pp	68.8%+0.2pp	67.8%-1.4pp	68.8%+0.1pp
Operating Margin	21.6%+5.5pp	21.2%+1.4pp	15.6%+0.8pp	20.7%+3.3pp	16.2%+3.6pp	19.8%+2.2pp	14.8%-0.9pp	17.4%-2.2pp
Net Margin	16.6%+0.9pp	25.7%+11.3pp	12.7%+0.3pp	14.9%+3.8pp	15.7%+7.9pp	14.4%+1.6pp	12.3%-1.2pp	11.1%-3.2pp
Return on Equity	3.6%+0.1pp	5.2%+2.1pp	2.8%+0.2pp	3.2%+1.0pp	3.5%+2.0pp	3.0%+0.6pp	2.6%0.0pp	2.3%-0.4pp
Return on Assets	2.0%+0.1pp	3.0%+1.4pp	1.5%+0.1pp	1.8%+0.5pp	1.9%+1.0pp	1.7%+0.3pp	1.4%0.0pp	1.2%-0.3pp
Current Ratio	1.24-0.1x	1.90+0.4x	1.62+0.5x	1.510.0x	1.37-0.2x	1.45-0.2x	1.08-0.2x	1.48+0.1x
Debt-to-Equity	0.44-0.1x	0.420.0x	0.460.0x	0.480.0x	0.50+0.1x	0.470.0x	0.410.0x	0.450.0x
Asset Turnover	0.120.0x	0.120.0x	0.120.0x	0.120.0x	0.120.0x	0.120.0x	0.120.0x	0.110.0x
FCF Margin	23.5%+1.2pp	3.3%-4.3pp	19.2%-6.7pp	22.9%+3.4pp	22.3%+6.3pp	7.6%+8.0pp	25.8%+7.3pp	19.6%+5.2pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Boston Scientific Corporation BSX	FY2025	$20.1B	$2.9B	14.4%	$61.7B	65/100
Stryker Corporation SYK	FY2025	$25.1B	$3.2B	12.9%	$105.6B	67/100
Medtronic plc MDT	FY2026	$36.4B	$5K	0.0%	$110.5B	63/100
Edwards Lifesciences Corp EW	FY2025	$6.1B	$1.1B	17.7%	$49.1B	73/100
Abbott Laboratories ABT	FY2025	$44.3B	$6.5B	14.7%	$167.3B	69/100

Where Boston Scientific Corporation Ranks

Frequently Asked Questions

What is Boston Scientific Corporation's annual revenue?

Boston Scientific Corporation (BSX) reported $20.1B in total revenue for fiscal year 2025. This represents a 19.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Boston Scientific Corporation's revenue growing?

Boston Scientific Corporation (BSX) revenue grew by 19.9% year-over-year, from $16.7B to $20.1B in fiscal year 2025.

Is Boston Scientific Corporation profitable?

Yes, Boston Scientific Corporation (BSX) reported a net income of $2.9B in fiscal year 2025, with a net profit margin of 14.4%.

What is Boston Scientific Corporation's EBITDA?

Boston Scientific Corporation (BSX) had EBITDA of $5.0B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Boston Scientific Corporation have?

As of fiscal year 2025, Boston Scientific Corporation (BSX) had $2.0B in cash and equivalents against $11.1B in long-term debt.

What is Boston Scientific Corporation's gross margin?

Boston Scientific Corporation (BSX) had a gross margin of 69.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Boston Scientific Corporation's operating margin?

Boston Scientific Corporation (BSX) had an operating margin of 18.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Boston Scientific Corporation's net profit margin?

Boston Scientific Corporation (BSX) had a net profit margin of 14.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Boston Scientific Corporation's return on equity (ROE)?

Boston Scientific Corporation (BSX) has a return on equity of 11.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Boston Scientific Corporation's free cash flow?

Boston Scientific Corporation (BSX) generated $3.7B in free cash flow during fiscal year 2025. This represents a 38.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Boston Scientific Corporation's operating cash flow?

Boston Scientific Corporation (BSX) generated $4.5B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Boston Scientific Corporation's total assets?

Boston Scientific Corporation (BSX) had $43.7B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Boston Scientific Corporation's capital expenditures?

Boston Scientific Corporation (BSX) invested $876.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Boston Scientific Corporation spend on research and development?

Boston Scientific Corporation (BSX) invested $2.1B in research and development during fiscal year 2025.

How many shares does Boston Scientific Corporation have outstanding?

Boston Scientific Corporation (BSX) had 1.48B shares outstanding as of fiscal year 2025.

What is Boston Scientific Corporation's current ratio?

Boston Scientific Corporation (BSX) had a current ratio of 1.62 as of fiscal year 2025, which is generally considered healthy.

What is Boston Scientific Corporation's debt-to-equity ratio?

Boston Scientific Corporation (BSX) had a debt-to-equity ratio of 0.46 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Boston Scientific Corporation's return on assets (ROA)?

Boston Scientific Corporation (BSX) had a return on assets of 6.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Boston Scientific Corporation's P/E ratio?

Boston Scientific Corporation (BSX) trades at 16.8x earnings, its market capitalization divided by net income of $3.7B net income, trailing 12 months to June 30, 2026. The market capitalization is $61.7B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Boston Scientific Corporation's price-to-sales ratio?

Boston Scientific Corporation (BSX) trades at 2.9x sales, its market capitalization divided by revenue of $21.0B revenue, trailing 12 months to June 30, 2026. The market capitalization is $61.7B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Boston Scientific Corporation's Altman Z-Score?

Boston Scientific Corporation (BSX) has an Altman Z-Score of 2.91, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Boston Scientific Corporation's Piotroski F-Score?

Boston Scientific Corporation (BSX) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Boston Scientific Corporation's earnings high quality?

Boston Scientific Corporation (BSX) has an earnings quality ratio of 1.57x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Boston Scientific Corporation cover its interest payments?

Boston Scientific Corporation (BSX) has an interest coverage ratio of 10.35x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Boston Scientific Corporation?

Boston Scientific Corporation (BSX) scores 65 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.